• Filing Date: 2021-03-31
  • Form Type: 10-K
  • Description: Annual report
v3.21.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Preferred Stock
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Non - controlling Interest in Subsidiary [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2018 $ 12,000 $ 107,962,000 $ (7,000) $ (100,392,000) $ 7,575,000
Balance, shares at Dec. 31, 2018 581,000          
Issuance of common stock, net $ 12,000 7,292,000 $ 7,304,000
Issuance of common stock, net, shares 610,000        
Stock based payments, net of tax effect 306,000 $ 306,000
Stock based payments, net of tax effect, shares 15,000          
Other comprehensive loss 7,000 7,000
Net income (loss) (2,889,000) (2,889,000)
Balance at Dec. 31, 2019 $ 24,000 115,560,000 (103,281,000) 12,303,000
Balance, shares at Dec. 31, 2019 1,206,000          
Issuance of common stock, net $ 68,000 20,127,000 $ 20,196,000
Issuance of common stock, net, shares 3,434,000        
Conversion of preferred stock $ 13,000 (13,000)
Conversion of preferred stock, shares 663,000 (4,000)          
Stock based payments, net of tax effect $ 1,000 397,000 398,000
Stock based payments, net of tax effect, shares 50,000          
Acquisition of Impact BioMedical, Inc. $ 10,000 $ 1,000 38,309,000 3,911,000 42,231,000
Acquisition of Impact BioMedical, Inc., shares 483,000 47,000          
Net income (loss) (481,000) 1,899,000 1,418,000
Balance at Dec. 31, 2020 $ 116,000 $ 1,000 $ 174,380,000 $ 3,430,000 $ (101,382,000) $ 76,545,000
Balance, shares at Dec. 31, 2020 5,836,000 43,000